Nitrofurantoin for Uncomplicated Lower Urinary Tract Infection
For adults with normal renal function (CrCl ≥60 mL/min) and uncomplicated lower UTI, prescribe nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days. 1
Recommended Dosing
The standard regimen is:
- Nitrofurantoin monohydrate/macrocrystals: 100 mg orally twice daily for 5 days 1
- Alternative formulations include nitrofurantoin macrocrystals 50-100 mg four times daily for 5 days 2
This 5-day regimen demonstrates clinical cure rates of 90-93% and microbiological cure rates of 86-92% 1. The IDSA/ESMID guidelines position nitrofurantoin as a first-line agent due to minimal resistance patterns and low propensity for collateral damage to gut microbiota 1.
Key Contraindications
Renal Function
Nitrofurantoin is contraindicated when creatinine clearance is <60 mL/min 3. This FDA contraindication exists because:
- Reduced urinary drug concentrations may compromise efficacy 4
- Increased risk of peripheral neuropathy with renal impairment 3
- Clinical failure rates increase significantly with declining renal function (5% increased odds per 10 mL/min decrease in eGFR) 5
Important caveat: The evidence supporting the 60 mL/min cutoff is weak and based on limited pharmacokinetic data from 1968 4. Recent studies suggest nitrofurantoin may be effective down to CrCl 40 mL/min 4, 6, but the FDA contraindication remains in effect and should be followed in clinical practice.
Other Absolute Contraindications
- Pregnancy at term (38-42 weeks gestation) or during labor/delivery 3
- Neonates under 1 month of age 3
- Known hypersensitivity to nitrofurantoin 3
- Oliguria, anuria, or significant renal impairment 3
Conditions Requiring Caution
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Risk of hemolytic anemia 3
- Anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency: Increased peripheral neuropathy risk 3
- Debilitating diseases: Higher risk of adverse effects 3
Common Adverse Effects
Gastrointestinal (Most Frequent)
- Nausea, vomiting, anorexia (most common, dose-related) 1, 3
- Abdominal pain and diarrhea (less common) 3
- Can be minimized by taking with food and dose reduction 3
- Adverse event rates in clinical trials: 28-34% 1
Pulmonary Reactions (Most Serious)
Acute pulmonary reactions (within first week):
- Fever, chills, cough, chest pain, dyspnea 3
- Pulmonary infiltrates, pleural effusion, eosinophilia 3
- Usually reversible with cessation 3
Chronic pulmonary reactions (after ≥6 months continuous use):
- Insidious onset: malaise, dyspnea on exertion, cough 3
- Diffuse interstitial pneumonitis or fibrosis 3
- May be irreversible even after stopping the drug 3
- Risk increases with delayed recognition 3
Neurologic
- Peripheral neuropathy: May become severe or irreversible; fatalities reported 3
- Headache, dizziness, drowsiness 1, 3
- Rare: benign intracranial hypertension, optic neuritis 3
Hepatic (Rare but Serious)
- Hepatitis, cholestatic jaundice, chronic active hepatitis, hepatic necrosis 3
Hematologic
- Hemolytic anemia (especially with G6PD deficiency) 3
- Agranulocytosis, leukopenia, thrombocytopenia (rare) 3
- Megaloblastic anemia 3
Dermatologic
- Rash, urticaria, pruritus 3
- Rare: Stevens-Johnson syndrome, exfoliative dermatitis 3
- Transient alopecia 3
Clinical Efficacy Context
Nitrofurantoin demonstrates equivalent efficacy to trimethoprim-sulfamethoxazole (90% vs 90% clinical cure) and superior microbiological cure compared to fosfomycin (86% vs 78%) 1. The 2024 WikiGuidelines and 2024 EAU guidelines both recommend nitrofurantoin as first-line therapy for uncomplicated cystitis due to its excellent efficacy profile and minimal ecological impact 7, 2.
Critical pitfall: Do not use nitrofurantoin for pyelonephritis or complicated UTI—it achieves inadequate tissue concentrations outside the urinary tract 7, 2.